VERY-LOW-DOSE HEPATITIS B VACCINE IN NEWBORN INFANTS: AN ECONOMIC OPTION FOR CONTROL IN ENDEMIC AREAS
1987; Elsevier BV; Volume: 329; Issue: 8523 Linguagem: Inglês
10.1016/s0140-6736(87)90712-4
ISSN1474-547X
AutoresChristopher D. Moyes, Mary Dimitrakakis, A Milne, PaulN. Goldwater, Neil Pearce,
Tópico(s)Vaccine Coverage and Hesitancy
ResumoThree 1 μg or 2 μg doses of Merck, Sharp and Dohme plasma vaccine were given to 119 infants of mothers negative for antibody to hepatitis B surface antigen (anti-HBs). Anti-HBs antibodies developed in 25/29 (86%) infants given 1 μg and in 86/90 (96%) given 2 μg doses. Levels of anti-HBs achieved by three 2 μg doses were similar to those that have been reported for conventional 10 μg doses. Similar levels were recorded from infants of anti-HBs-positive mothers, which suggests that maternal antibody does not interfere with the infant's immune response to low doses of vaccine. Three 2 μg doses of vaccine in infancy produce satisfactory immunogenicity and make possible economic control of hepatitis B in endemic areas.
Referência(s)